In TOP2A-positive/HLA-I–negative cases, patients with SCLC may have poor prognosis; in contrast, in TOP2A-negative/HLA-I–positive cases, patients may achieve increased survival and benefit from immunotherapy, which is in accordance with coefficients of the corresponding gene in our proposed model. Here, TOP2A is linked to small cell lung carcinoma.